eBook: Sample Chaos in Oncology Clinical Trials

Make sense of biomarker samples in oncology clinical trials

Oncology studies, like other biomarker-rich therapeutic areas, generate multiple sample types and derivatives that travel to diverse specialty labs, screening labs, and biorepositories. As research and operations teams often lack centralized visibility into sample collection, processing, and storage status, they face the unenviable task of overcoming sample and data chaos.

Within this eBook, authored for oncology translational research and clinical operations teams, Precision experts examine the various impacts sample chaos can have on complex oncology clinical trials, answer questions such as:

• “Are all clinical trial sites collecting the samples we expect and need?”
• “When will enough samples arrive to trigger batch processing?”
• “Were these samples properly consented?”
• “How many whole blood samples with a particular mutation do we have across all Phase I studies?”
• “Can we report sample expiration status across all of our contracted biorepositories?”

Download the eBook to learn easy-to-implement approaches for keeping track of clinical samples without resorting to headache-inducing spreadsheets.  

As veterans of clinical trial data management, the authors describe ways to break down data silos to help generate both scientific and operational insights for oncology research teams. Discover how a well-annotated virtual repository can be a powerful tool for more efficient drug development.

Precision for Medicine has redefined the clinical research organization. Purpose-built for precision medicine, we integrate deep scientific knowledge, laboratory expertise, and clinical trial excellence, using advanced data sciences to inform every step. This maximizes insight into patient biology, delivering more predictable trial outcomes and accelerating clinical development. We apply our expertise to trials at all stages—from early development to late phase—with particular experience in oncology and rare disease, striking tumors on a molecular level, and using rarefied thinking to recruit and run widely dispersed trials. With trials in more than 70 countries, we stand ready to help accelerate your life-changing treatments anywhere around the globe.